Ensysce Biosciences vs Inmed Pharmaceuticals
Ensysce Biosciences and Inmed Pharmaceuticals are similar in size: $5.1m and $4.9m of revenue in their latest fiscal years. Inmed Pharmaceuticals grew faster (7.5% against -2.8%). Inmed Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -34.4% against -200.8%.
| Latest fiscal year | Ensysce BiosciencesENSC, 2025 | Inmed PharmaceuticalsINM, 2025 |
|---|---|---|
| Revenue | $5.1m | $4.9m |
| Revenue growth | -2.8% | 7.5% |
| Net income | −$10.2m | −$1.7m |
| Operating margin | -202.1% | — |
| Net margin | -200.8% | -34.4% |
| Return on equity | — | -15.0% |
| Free cash flow | −$7.9m | −$8.1m |
| Cash | $4.3m | $10.7m |
| Total debt | $306,708 | $0 |
| Debt to equity | 9.5% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 6 |
| Market value | $5.9m | $9.2m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 2 buys, 0 sales | 49 buys, 0 sales |